Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease

详细信息    查看全文

• 作者：Dong Jin Go ; Jin Kyun Park ; Eun Ha Kang ; Hyun Mi Kwon…
• 关键词：Dermatomyositis ; Amyopathic dermatomyositis ; Interstitial lung disease ; Cyclosporine ; Survival
• 刊名：Rheumatology International
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：36
• 期：1
• 页码：125-131
• 全文大小：431 KB
• 参考文献：1.Marie I, Hatron P, Dominique S, Cherin P, Mouthon L, Menard JF (2011) Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 63:3439–3447PubMed CrossRef
  2.Fathi M, Vikgren J, Boijsen M, Tylen U, Jorfeldt L, Tornling G et al (2008) Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 59:677–685PubMed CrossRef
  3.Chen I-J, Wu Y-JJ, Lin C-W, Fan K-W, Luo S-F, Ho H-H et al (2009) Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 28:639–646PubMed CrossRef
  4.Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, Cadranel J, Delaval P, Ternamian P et al (2003) Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 22:245–250PubMed CrossRef
  5.Vij R, Strek ME (2013) Diagnosis and treatment of connective tissue disease-associated interstitial lung disease connective tissue-interstitial lung disease. Chest 143:814–824PubMed PubMedCentral CrossRef
  6.Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46:626–636PubMed CrossRef
  7.Suda T, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Naito T et al (2006) Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J 28:1005–1012PubMed CrossRef
  8.Kang E, Lee E, Shin K, Im C, Chung D, Han S et al (2005) Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology 44:1282–1286PubMed CrossRef
  9.Marie I, Hachulla E, Cherin P, Dominique S, Hatron PY, Hellot MF et al (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47:614–622PubMed CrossRef
  10.Nawata Y, Kurasawa K, Takabayashi K, Miike S, Watanabe N, Hiraguri M et al (1999) Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine treatment with cyclosporine. J Rheumatol 26:1527–1533PubMed
  11.Fujisawa T, Suda T, Nakamura Y, Enomoto N, Ide K, Toyoshima M et al (2005) Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 32:58–64PubMed
  12.Takada K, Kishi J, Miyasaka N (2007) Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis/polymyositis: a retrospective study. Mod Rheumatol 17:123–130PubMed CrossRef
  13.Kotani T, Makino S, Takeuchi T, Kagitani M, Shoda T, Hata A et al (2008) Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol 35:254–259PubMed
  14.Takada K, Nagasaka K, Miyasaka N (2005) Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 38:383–392PubMed CrossRef
  15.Maeda K, Kimura R, Komuta K, Igarashi T (1997) Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand J Rheumatol 26:24–29PubMed CrossRef
  16.Labirua-Iturburu A, Selva-O’Callaghan A, Martinez-Gomez X, Trallero-Araguás E, Labrador-Horrillo M, Vilardell-Tarrés M (2012) Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin Exp Rheumatol 31:436–439
  17.Bohan A, Peter JB, Bowman RL, Pearson CM (1977) A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 56:255–286PubMed CrossRef
  18.Mino M, Noma S, Taguchi Y, Tomii K, Kohri Y, Oida K (1997) Pulmonary involvement in polymyositis and dermatomyositis: sequential evaluation with CT. AJR Am J Roentgenol 169:83–87PubMed CrossRef
  19.Arakawa H, Yamada H, Kurihara Y, Nakajima Y, Takeda A, Fukushima Y et al (2003) Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositisserial high-resolution CT findings and functional correlation. Chest 123:1096–1103PubMed CrossRef
  20.Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL et al (1997) Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 169:977–983PubMed CrossRef
  21.Kurasawa K, Nawata Y, Takabayashi K, Kumano K, Kita Y, Takiguchi Y et al (2002) Activation of pulmonary T cells in corticosteroid-resistant and-sensitive interstitial pneumonitis in dermatomyositis/polymyositis. Clin Exp Immunol 129:541–548PubMed PubMedCentral CrossRef
  22.Yamadori I, Fujita J, Kajitani H, Bandoh S, Tokuda M, Ohtsuki Y et al (2001) Lymphocyte subsets in lung tissues of interstitial pneumonia associated with untreated polymyositis/dermatomyositis. Rheumatol Int 21:89–93PubMed CrossRef
  23.Connors GR, Christopher-Stine L, Oddis CV, Danoff SK (2010) Interstitial lung disease associated with the idiopathic inflammatory myopathies what progress has been made in the past 35 years? Chest 138:1464–1474PubMed CrossRef
  24.Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M et al (2005) Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 32:1719–1726PubMed
  25.Kotani T, Takeuchi T, Makino S, Hata K, Yoshida S, Nagai K et al (2011) Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol 30:1021–1028PubMed CrossRef
  26.Nagasaka K, Harigai M, Tateishi M, Hara M, Yoshizawa Y, Koike T et al (2003) Efficacy of combination treatment with cyclosporin A and corticosteroids for acute interstitial pneumonitis associated with dermatomyositis. Mod Rheumatol 13:231–238PubMed CrossRef
  27.Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard J-F et al (2012) Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 41:890–899PubMed CrossRef
  28.Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T et al (2011) Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 147:391–398PubMed CrossRef
  29.Mimori T, Nakashima R, Hosono Y (2012) Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep 14:264–274PubMed CrossRef
  
• 作者单位：Dong Jin Go (1) (2)
  Jin Kyun Park (1) (2)
  Eun Ha Kang (3)
  Hyun Mi Kwon (1)
  Yun Jong Lee (3)
  Yeong Wook Song (1) (2)
  Eun Bong Lee (1)
  
  1. Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
  2. Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Medical Research Institute, Seoul National University, Seoul, Korea
  3. Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
  
• 刊物主题：Rheumatology;
• 出版者：Springer Berlin Heidelberg
• ISSN：1437-160X

文摘

Interstitial lung disease (ILD) is the most common cause of death in dermatomyositis (DM). Cyclosporine A (CsA) has shown to be effective in DM-associated ILD (DM-ILD). This study aimed to define the optimal time of CsA administration. A total of 47 patients with DM-ILD, who were treated with CsA at Seoul National University Hospital between January 1998 and June 2013, were enrolled. ILD was diagnosed based on typical chest high-resolution computed tomography (HRCT) findings. Patients with early and delayed CsA treatment were compared in regard to the mortality and ILD progression on HRCT. The early (n = 16) and the delayed treatment group (n = 31) did not differ in regard to baseline clinical characteristics including HRCT scores and pulmonary function. Patients with clinically amyopathic DM (CADM) were more common in the early treatment group. The mortality rate was significantly lower in the early treatment group than in the delayed treatment group (p = 0.009). The survival benefit of early CsA treatment remained significant even after adjusting for age, degree of dyspnea, CADM status, and the year of CsA treatment (hazard ratio 0.057, 95 % confidence interval 0.007–0.472). CsA stabilized disease progression on HRCT in the early treatment group (p = 0.738). Delay in CsA treatment is associated with a worse survival in patients with DM-ILD. Early CsA treatment should be considered at DM-ILD diagnosis especially in patients at a higher risk of developing a rapidly progressive ILD.